255 related articles for article (PubMed ID: 9178886)
1. Inhibition of apoptosis by normal and aberrant Fli-1 and erg proteins involved in human solid tumors and leukemias.
Yi H; Fujimura Y; Ouchida M; Prasad DD; Rao VN; Reddy ES
Oncogene; 1997 Mar; 14(11):1259-68. PubMed ID: 9178886
[TBL] [Abstract][Full Text] [Related]
2. A second Ewing's sarcoma translocation, t(21;22), fuses the EWS gene to another ETS-family transcription factor, ERG.
Sorensen PH; Lessnick SL; Lopez-Terrada D; Liu XF; Triche TJ; Denny CT
Nat Genet; 1994 Feb; 6(2):146-51. PubMed ID: 8162068
[TBL] [Abstract][Full Text] [Related]
3. EWS/FLI-1 antagonists induce growth inhibition of Ewing tumor cells in vitro.
Kovar H; Aryee DN; Jug G; Henöckl C; Schemper M; Delattre O; Thomas G; Gadner H
Cell Growth Differ; 1996 Apr; 7(4):429-37. PubMed ID: 9052984
[TBL] [Abstract][Full Text] [Related]
4. EWS/Fli-1 chimeric protein is a transcriptional activator.
Ohno T; Rao VN; Reddy ES
Cancer Res; 1993 Dec; 53(24):5859-63. PubMed ID: 7503813
[TBL] [Abstract][Full Text] [Related]
5. Multiple domains mediate transformation by the Ewing's sarcoma EWS/FLI-1 fusion gene.
Lessnick SL; Braun BS; Denny CT; May WA
Oncogene; 1995 Feb; 10(3):423-31. PubMed ID: 7845667
[TBL] [Abstract][Full Text] [Related]
6. Loss of tumorigenicity of Ewing's sarcoma cells expressing antisense RNA to EWS-fusion transcripts.
Ouchida M; Ohno T; Fujimura Y; Rao VN; Reddy ES
Oncogene; 1995 Sep; 11(6):1049-54. PubMed ID: 7566963
[TBL] [Abstract][Full Text] [Related]
7. Induction of tenascin-C by tumor-specific EWS-ETS fusion genes.
Watanabe G; Nishimori H; Irifune H; Sasaki Y; Ishida S; Zembutsu H; Tanaka T; Kawaguchi S; Wada T; Hata J; Kusakabe M; Yoshida K; Nakamura Y; Tokino T
Genes Chromosomes Cancer; 2003 Mar; 36(3):224-32. PubMed ID: 12557222
[TBL] [Abstract][Full Text] [Related]
8. Regulatory role of mevalonate and N-linked glycosylation in proliferation and expression of the EWS/FLI-1 fusion protein in Ewing's sarcoma cells.
Wang M; Xie Y; Girnita L; Nilsson G; Dricu A; Wejde J; Larsson O
Exp Cell Res; 1999 Jan; 246(1):38-46. PubMed ID: 9882513
[TBL] [Abstract][Full Text] [Related]
9. Repression of the gene encoding the TGF-beta type II receptor is a major target of the EWS-FLI1 oncoprotein.
Hahm KB; Cho K; Lee C; Im YH; Chang J; Choi SG; Sorensen PH; Thiele CJ; Kim SJ
Nat Genet; 1999 Oct; 23(2):222-7. PubMed ID: 10508522
[TBL] [Abstract][Full Text] [Related]
10. Biphenotypic sarcomas with myogenic and neural differentiation express the Ewing's sarcoma EWS/FLI1 fusion gene.
Sorensen PH; Shimada H; Liu XF; Lim JF; Thomas G; Triche TJ
Cancer Res; 1995 Mar; 55(6):1385-92. PubMed ID: 7882340
[TBL] [Abstract][Full Text] [Related]
11. Downregulation and forced expression of EWS-Fli1 fusion gene results in changes in the expression of G(1)regulatory genes.
Matsumoto Y; Tanaka K; Nakatani F; Matsunobu T; Matsuda S; Iwamoto Y
Br J Cancer; 2001 Mar; 84(6):768-75. PubMed ID: 11259090
[TBL] [Abstract][Full Text] [Related]
12. Differential transactivation by alternative EWS-FLI1 fusion proteins correlates with clinical heterogeneity in Ewing's sarcoma.
Lin PP; Brody RI; Hamelin AC; Bradner JE; Healey JH; Ladanyi M
Cancer Res; 1999 Apr; 59(7):1428-32. PubMed ID: 10197607
[TBL] [Abstract][Full Text] [Related]
13. Upregulation of Id2, an oncogenic helix-loop-helix protein, is mediated by the chimeric EWS/ets protein in Ewing sarcoma.
Fukuma M; Okita H; Hata J; Umezawa A
Oncogene; 2003 Jan; 22(1):1-9. PubMed ID: 12527902
[TBL] [Abstract][Full Text] [Related]
14. Differential regulation of the response to DNA damage in Ewing's sarcoma cells by ETS1 and EWS/FLI-1.
Soldatenkov VA; Trofimova IN; Rouzaut A; McDermott F; Dritschilo A; Notario V
Oncogene; 2002 Apr; 21(18):2890-5. PubMed ID: 11973649
[TBL] [Abstract][Full Text] [Related]
15. EWS-Fli1 antisense oligodeoxynucleotide inhibits proliferation of human Ewing's sarcoma and primitive neuroectodermal tumor cells.
Tanaka K; Iwakuma T; Harimaya K; Sato H; Iwamoto Y
J Clin Invest; 1997 Jan; 99(2):239-47. PubMed ID: 9005992
[TBL] [Abstract][Full Text] [Related]
16. The N-terminal domain of human TAFII68 displays transactivation and oncogenic properties.
Bertolotti A; Bell B; Tora L
Oncogene; 1999 Dec; 18(56):8000-10. PubMed ID: 10637511
[TBL] [Abstract][Full Text] [Related]
17. TLS/FUS fusion domain of TLS/FUS-erg chimeric protein resulting from the t(16;21) chromosomal translocation in human myeloid leukemia functions as a transcriptional activation domain.
Prasad DD; Ouchida M; Lee L; Rao VN; Reddy ES
Oncogene; 1994 Dec; 9(12):3717-29. PubMed ID: 7970732
[TBL] [Abstract][Full Text] [Related]
18. GSTM4 is a microsatellite-containing EWS/FLI target involved in Ewing's sarcoma oncogenesis and therapeutic resistance.
Luo W; Gangwal K; Sankar S; Boucher KM; Thomas D; Lessnick SL
Oncogene; 2009 Nov; 28(46):4126-32. PubMed ID: 19718047
[TBL] [Abstract][Full Text] [Related]
19. Suppression of the Ewing's sarcoma phenotype by FLI1/ERF repressor hybrids.
Athanasiou M; LeGallic L; Watson DK; Blair DG; Mavrothalassitis G
Cancer Gene Ther; 2000 Aug; 7(8):1188-95. PubMed ID: 10975680
[TBL] [Abstract][Full Text] [Related]
20. EAT-2 is a novel SH2 domain containing protein that is up regulated by Ewing's sarcoma EWS/FLI1 fusion gene.
Thompson AD; Braun BS; Arvand A; Stewart SD; May WA; Chen E; Korenberg J; Denny C
Oncogene; 1996 Dec; 13(12):2649-58. PubMed ID: 9000139
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
